Abstract 402: Pasireotide reduces chemoresistance in pancreatic tumor cells by inhibiting the synthesis and secretion of growth factors from tumor associated fibroblasts
Camille Duluc(Inserm), Corinne Bousquet(Centre National de la Recherche Scientifique), Aurélie Perraud(Centre Hospitalier Universitaire de Limoges), Mounira Chalabi(Université Toulouse III - Paul Sabatier), Siham Moatassim(Inserm), Stéphane Pyronnet(Centre National de la Recherche Scientifique), Marie‐Bernadette Delisle(Inserm), Herbert Schmid(Novartis (Switzerland)), Muriel Mathonnet(Inserm), Yvan Martineau(Centre National de la Recherche Scientifique), Florence Breibach(Pharmacochimie et Biologie pour le Développement)
Cited by 0
Related Papers
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284